CD19 and acute lymphoblastic leukemia: Finally, theFood and Drug Administration (FDA) in 2017 approved CAR T-cell products(Kymriah manufactured by Novartis and Yescarta manufactured by Kite Pharma)targeting CD19 for the treatment of acute lymphoblastic leukemia (ALL).